Richardson Electronics (RELL) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Apr, 2026Executive summary
Achieved seven consecutive quarters of year-over-year sales growth, with Q3 FY26 net sales up 3.1% to $55.5 million compared to the prior year.
Net income for Q3 FY26 was $0.9 million, reversing a $2.1 million loss in Q3 FY25; EPS was $0.07 per diluted share.
Gross margin improved to 31.9% in Q3 FY26 from 31.0% in Q3 FY25, attributed to favorable product mix and lower manufacturing under absorption.
Backlog at February 28, 2026, reached $151.2 million, up 11.4% sequentially and highest since FY2023.
Board declared a $0.06 per share quarterly cash dividend, payable May 27, 2026.
Financial highlights
Q3 FY26 net sales: $55.5 million, up 3.1% year-over-year; excluding Healthcare, net sales rose 6.0%.
Q3 FY26 net income: $0.9 million; EPS: $0.07 per diluted share; EBITDA for Q3 was $2.2 million, up from negative $2.1 million.
Cash and cash equivalents at quarter-end were $29.5 million, with no outstanding debt.
Operating income for Q3 FY26 was $1.5 million, compared to a $2.7 million loss in Q3 FY25.
Backlog at Q3 FY26: $151.2 million, highest since FY2023 and up over 150% since FY2019.
Outlook and guidance
Backlog and order activity remain strong, supporting confidence for Q4 and FY27, with expectations for double-digit revenue growth in GES.
Sustained demand expected in power management, energy transition, and semiconductor applications.
Management expects existing liquidity and cash flows to meet capital and working capital needs for the next twelve months.
Made in America strategy and AI-driven efficiency initiatives expected to support future growth and profitability.
Latest events from Richardson Electronics
- Q2 FY26 sales up 5.7% to $52.3M, GES up 39%, backlog $135.7M, $0.06 dividend, no debt.RELL
Q2 202613 Apr 2026 - Sales and profits fell in 2024, but margin, cash flow, and backlog support a positive 2025 outlook.RELL
Q4 20242 Feb 2026 - Q1 FY25 sales up 2.2% to $53.7M, with GES and Healthcare growth and a strong, debt-free balance sheet.RELL
Q1 202519 Jan 2026 - Q3 net sales up 2.7% YoY, strong PMT/Canvys, $4.9M Healthcare loss, cash $36.7M, no debt.RELL
Q3 202516 Jan 2026 - Q2 FY25 sales up 12.1% to $49.5M, led by 129% GES growth and improved margins.RELL
Q2 202510 Jan 2026 - Shareholders will vote on director elections, auditor ratification, compensation, and capital structure changes.RELL
Proxy Filing1 Dec 2025 - Proxy seeks approval for director elections, auditor, compensation, and share increases.RELL
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and executive pay are key 2024 meeting topics.RELL
Proxy Filing1 Dec 2025 - Annual meeting to elect directors, ratify auditor, and approve executive pay on October 8, 2024.RELL
Proxy Filing1 Dec 2025